Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

ALCL-VBL (anaplastic large cell lymphoma)

Clinical study into a new treatment for ALK+ anaplastic large cell lymphoma.
Who can enter
  • Children with ALK+ anaplastic large-cell lymphoma (ALCL) at standard risk at initial diagnosis.
  • Children up to 18 years old.


The aim of this study is to improve the treatment of children with lymphoma. We will investigate whether treatment with only vinblastine gives the same result as treatment with chemotherapy courses with different drugs. We will also look at the side effects of treatment with vinblastine alone.


Vinblastine is approved for treatment of different types of tumors and lymphomas in adults and children. In a previous study, vinblastine was also tested in children with ALCL where the disease had returned after previous treatment (recurrence). After treatment with vinblastine, about 80% of these patients had no recurrence. In this study, we want to see if vinblastine also works well in children who have not had any previous treatment.

Normally, we treat children with standard-risk ALCL at initial diagnosis with chemotherapy courses of various drugs. This treatment gives good results, but also causes many side effects. In this study, we want to see if treatment with vinblastine alone has as good a result as chemotherapy courses with several drugs. We will also look at the side effects.

All children participating in the study will be treated with the medicine vinblastine. The treatment lasts two years.

In order to participate in a study please refer to your/your child’s doctor.
For international patients: please feel welcome to contact our International Office.

Last reviewed

November 4, 2022